A federal appeals court has rejected a drug manufacturer’s appeal and affirmed a judge’s order that Actavis PLC keep distributing its widely used Alzheimer’s medication until after its patent expires this summer.
New York Attorney General Eric Schneiderman had sought the order and called the Court of Appeals ruling a victory for consumers. His office says the drug Namenda should remain on shelves 30 days after the patent expires July 11.
He alleged anti-trust and state law violations by Actavis in an effort to push patients to its new patented drug and avoid losses from cheaper generics.
Dublin-based Actavis says its new drug Namenda XR is better and demand is growing. It’s taken once daily, not twice daily.
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Woolworths Calls On ACCC To Conduct a “Fact-Based” Inquiry into Supermarket Competition
May 22, 2024 by
CPI
EU Chips Act Set to Attract Over €100 Billion in Private Investment by 2030
May 22, 2024 by
CPI
Brazil’s Antitrust Regulator Approves New Terms for Petrobras Agreement
May 22, 2024 by
CPI
Apple Challenges €1.84 Billion EU Fine Over App Store Restrictions
May 22, 2024 by
CPI
SEC Urges Lawmakers to Reject New Crypto Bill, Citing Market Risks
May 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI